FDA launches neuroscience program and Alzheimer’s prevention initiative

The U.S. Food and Drug Administration announced the launch of the Neuroscience Advancement and Innovation Nexus on Thursday 22 October 2026. According to the agency, the program was aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.

NAIN was designed to advance the science, tools and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system. It would bring together scientific and regulatory expertise from the FDA’s Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health.

The FDA said developing medical products for neuroscience indications involved complex scientific and clinical challenges. These included limited understanding of underlying biology, variable disease presentation and difficulty demonstrating meaningful clinical benefit, particularly for conditions that develop over many years. Advances in biomarkers, digital health technologies and other product development tools offered opportunities to address these challenges.

NAIN would cover conditions affecting the brain and nervous system broadly. These included neurologic and psychiatric disorders, substance use disorders and pain. The program would also support engagement with patients, industry, academia and other stakeholders.

The agency launched the Alzheimer’s Prevention Accelerator as NAIN’s inaugural initiative. It would focus on medical products that help delay or prevent Alzheimer’s disease and draw on perspectives from across the FDA. The initiative would engage patients and caregivers, researchers, industry, public-private partnerships and other government agencies.

According to Acting FDA Commissioner Kyle Diamantas, the launch reflected the agency’s commitment to keeping regulatory science and cross-center collaboration aligned with advances in neuroscience. The Alzheimer’s Prevention Accelerator would explore clinical trials for Alzheimer’s disease prevention and early-intervention drug development. It would emphasize trial populations, stage-appropriate endpoints and ways to demonstrate prevention or delay of cognitive decline due to Alzheimer’s disease.